Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 221 to 230 of 547 total matches.
In Brief: Neuropsychiatric Events with Montelukast
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
of suicidal behavior and other
serious neuropsychiatric events associated with its use.1
Montelukast ...
The FDA is requiring stronger warnings in the labeling of
the leukotriene receptor antagonist montelukast (Singulair,
and generics) about the risk of suicidal behavior and other
serious neuropsychiatric events associated with its use.
Comparison Table: Some Topical Drugs for Rosacea (online only)
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
in women
Apply once/day 481.60/30 g
637.50/30 g
Ivermectin – generic
Soolantra (Galderma)
1% cream Yes ...
View the Comparison Table: Some Topical Drugs for Rosacea
Med Lett Drugs Ther. 2024 Feb 5;66(1695):e22 doi:10.58347/tml.2024.1695c | Show Introduction Hide Introduction
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
therapy, addition of an inhaled corticosteroid
is recommended.1,2
CLINICAL STUDIES — In two 24-week ...
The FDA has approved Duaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA) formoterol
fumarate, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be
approved in the US for this indication.
Twirla - A New Contraceptive Patch
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
hormonal
contraceptives. Unscheduled bleeding/spotting lasting
≥1 day occurred in 60.4% of women in cycle ...
The FDA has approved Twirla (Agile Therapeutics),
a transdermal contraceptive patch containing the
estrogen ethinyl estradiol and the progestin
levonorgestrel, for use in women with a BMI <30 kg/m2.
It is the second contraceptive patch to become
available in the US; Xulane, a patch that delivers
ethinyl estradiol and the progestin norelgestromin,
has been available since 2014.
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
months), and an optimal sequence of treatment has
not been established.1,2
Some patients with advanced ...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022 (Issue 1660)
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
The 1.5% cream formulation of the Janus ...
The 1.5% cream formulation of the Janus kinase
(JAK) inhibitor ruxolitinib (Opzelura – Incyte) has
been approved by the FDA for topical treatment of
nonsegmental vitiligo (NSV) in patients ≥12 years old.
Opzelura is the first product to be approved by the
FDA for this indication. It was previously approved for
treatment of atopic dermatitis.
Loteprednol 0.25% (Eysuvis) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
inhibitors
(SSRIs). Dry eye disease is most prevalent in women
and older adults.1,2
STANDARD TREATMENT ...
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved for
this indication. Other formulations of loteprednol are
approved for treatment of steroid-responsive ocular
inflammatory conditions, inflammation after ocular
surgery, and seasonal allergic conjunctivitis.
Sotagliflozin (Inpefa) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
), an oral sodium-glucose cotransporter
1 and 2 (SGLT1/2) inhibitor, to reduce the risk of
hospitalization ...
The FDA has approved sotagliflozin (Inpefa –
Lexicon), an oral sodium-glucose cotransporter
1 and 2 (SGLT1/2) inhibitor, to reduce the risk of
hospitalization for heart failure (HF), urgent HF visits,
and cardiovascular death in adults with either HF
(with any left ventricular ejection fraction [LVEF]) or
type 2 diabetes, chronic kidney disease (CKD), and
other cardiovascular risk factors. Sotagliflozin is
the first dual SGLT1/2 inhibitor to be approved in the
US. Unlike SGLT2 inhibitors, it is not FDA-approved
to improve glycemic control in adults with type 2
diabetes....
Med Lett Drugs Ther. 2023 Jul 24;65(1681):114-6 doi:10.58347/tml.2023.1681b | Show Introduction Hide Introduction
Viloxazine ER (Qelbree) for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
effects.1 Nonstimulants can
be used as initial monotherapy, in combination with
stimulants, or when ...
The FDA has approved viloxazine extended-release
capsules (Qelbree – Supernus) for treatment of
attention-deficit/hyperactivity disorder (ADHD) in
children 6-17 years old. Viloxazine is the second
selective norepinephrine reuptake inhibitor to be
approved in the US for treatment of ADHD; atomoxetine
(Strattera, and generics) was approved in 2002.
Ibrexafungerp (Brexafemme) for Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
mg once daily on days 1, 4, and
7), followed by a 6-month suppressive regimen of oral
fluconazole ...
The FDA has approved ibrexafungerp (Brexafemme –
Scynexis), a first-in-class triterpenoid antifungal
("fungerp"), for oral treatment of vulvovaginal candidiasis
in postmenarchal females.